“Exploitation of a novel host cell-based drug screen and natural product libraries for lead compound identification with anti-mycobacterial activity“– TTU TB, Deutsches Zentrum für Infektionsforschung (DZIF), BMBF, 2016-2020
“Validation of the γ-glutamylpolyamine synthetase GlnA3Mt as a promising target for development of novel anti-tubercular drugs (GPS-TBT)“ – BMBF, Programm: Targetvalidierung für die pharmazeutische Wirkstoffentwicklung, 2018-2020
“Clade specific virulence patterns of M. tuberculosis complex strains in human macrophages - Molecular mechanisms underlying phagosomal escape and induction of cell death”- Deutsche Forschungsgemeinschaft (DFG), Schwerpunktprogramm SPP1580, 2012-2018
“Isolation and Characterization of M. tuberculosis-induced lipid droplets from human primary macrophages“; Leibniz Center Infection (LCI), 2018-2021
“Discovering new therapeutic targets and drugs to combat AMR tuberculosis: proteomics characterization and drug screening of mycobacterium-infected macrophages" – Olav Thon Foundation, Norwegen (in Kooperation with T. Flo (N), M. Lerm (SE) und K. Prasad (IND), 2018-2022
„Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectives“ - MepAnti - Marie Skodowska-Curie Innovative Training Networks, 2020-2024
„NaPAnti: Development of natural product-based antibacterials targeting the sliding clamp DnaN“ - Bundesministerium für Bildung und Forschung, 2019-2022
„InhibitMycoRex: Optimization of mycobacterial thioredoxin reductase inhibitors, novel lead compounds against M. tuberculosis“ – Deutsches Zentrum für Infektionsforschung, 2019-2021
„ETBRA: European tuberculosis regimen accelerator“ – EU / Horizon 2020 (IMI), 2020-
Projects